The company's proprietary products in the United States include: NUVIGIL((R)) (armodafinil) Tablets [C-IV], TREANDA, AMRIX((R)) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA((R)) (fentanyl buccal tablet) [C-II], TRISENOX, GABITRIL((R)) (tiagabine hydrochloride), PROVIGIL((R)) (modafinil) Tablets [C-IV] and ACTIQ((R)) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available athttp://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, continuation of growth of the Cephalon Oncology business, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, econom
|SOURCE Cephalon, Inc.|
Copyright©2009 PR Newswire.
All rights reserved